immune mediated neuropathies
TRANSCRIPT
![Page 1: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/1.jpg)
Immune-Mediated Neuropathies
Naresh Mullaguri MDNeurology Resident Physician
University of Missouri
![Page 2: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/2.jpg)
GUILLAIN-BARRE´ SYNDROME• First described by Landry in
1859.• Guillain, Barre´, and Strohl
revisited the syndrome more than 50 years later.
• Acute inflammatory demyelinating polyradiculoneuropathy (AIDP).
• GBS =/= AIDP (as some pt’s have axonal loss without demyelination).
![Page 3: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/3.jpg)
• Two-thirds of patients with GBS have antecedent illness (respiratory or gastrointestinal infection) during the preceding month.
• Cytomegalovirus• Campylobacter jejuni• Mass vaccination have not been associated
with a measurable increase in GBS risk.
![Page 4: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/4.jpg)
Clinical features
• Neuropathic symptoms of GBS typically develop rapidly over several days or a few weeks.
• The nadir is reached within the first 2 weeks in about 50% of patients and within 4 weeks in about 90%.
• Tingling and numbness in the distal limbs weakness• Symptoms usually start in the feet and spread
proximally : ‘‘ascending’’ symmetrical paralysis.• Pain (low back pain or as a prickly, burning, or aching
pain of the limbs) is common in GBS and may overshadow the presence of weakness.
![Page 5: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/5.jpg)
Neurologic examination• Acute period : symmetrical
weakness (arms, legs, and sometimes facial muscles) and areflexia (70%).
• Mild sensory loss• Oculomotor paralysis• Autonomic instability• Acute worsening is very
rapid, with perceptible deterioration within only a few hours
![Page 6: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/6.jpg)
Variations of GBS
‘‘descending’’ pattern
Simultaneous weakness in both the arms and the legs
Pharyngeal-cervical-brachial variant
Miller Fisher syndrome (ophthalmoplegia, ataxia, and areflexia)
Multiple cranial neuropathies
Paraplegia or paraparesis
![Page 7: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/7.jpg)
Laboratory Features
Nonspecific:• Albuminocytologic dissociation : nonspecific
and is seen in infectious, neoplastic, vascular, and inflammatory disorders of the brain and spinal cord
• Mild pleocytosis• Gadolinium enhancement of the spinal roots
![Page 8: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/8.jpg)
EMG in GBS
• Early : small-amplitude compound muscle action potentials (CMAPs), prolonged distal motor latencies, and delayed or absent F waves.
• 2nd week : moderate or severe slowing of motor nerve conduction velocities, conduction block, and temporal dispersion
• Needle EMG examination of weak muscles should show reduced recruitment and high firing rate ofmotor units, although fibrillation potentials and positive sharp waves take 2 to 4 weeks to appear
![Page 9: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/9.jpg)
Differential Diagnosis of Guillain-Barre´ Syndrome
A number of diseases, notably myelopathies,neuromuscular junction disorders,and some acute neuropathies, domimic GBS
![Page 10: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/10.jpg)
![Page 11: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/11.jpg)
Management• Hospital admission and close monitoring (continuous pulse oximetry,
respiratory monitoring should include frequent bedside spirometry and measurements of inspiratory and expiratory pressures).
• Plasmapheresis and IV immunoglobulin (IVIg) appear to be equally efficacious in GBS when given within the first 1 to 2 weeks of the disease
• Corticosteroids are not effective• Selection of one over the other depends on the availability and the
relative contraindications• Renal disease or serious vascular risk factors, IVIg is often preferred• About 2% to 6% of patients with Guillain-Barre´ syndrome have a
subsequent relapse.
![Page 12: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/12.jpg)
CHRONIC INFLAMMATORYDEMYELINATING
POLYNEUROPATHIES• The clinical classification
is based on the clinical features, laboratory findings, and associated systemic diseases
• CIDP may also appear in the setting of several systemic diseases.
![Page 13: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/13.jpg)
![Page 14: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/14.jpg)
Classic (Idiopathic) ChronicInflammatory Demyelinating
Polyneuropathy
• Insidious clinical course: Weakness and sensory loss develop over many weeks or several months.
• Any age group but less prevalent in Pediatric population.
• No antecedent illness
![Page 15: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/15.jpg)
Clinical features
• Progressive limb weakness is a nearly universal presenting symptom.
• Patients may have increasing difficulty rising from a chair, going upstairs, opening jars, or lifting objects.
• Numbness and tingling in the hands and feet accompany the weakness.
• Pain is infrequent.
![Page 16: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/16.jpg)
Neurological examination
• Symmetric proximal and distal weakness affecting both arms and legs.
• Facial or extraocular weakness is uncommon.• Bulbar and respiratory weakness are also rare.• Reduced or absent DTR’s• Distal sensory loss is common on examination
![Page 17: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/17.jpg)
EMG in CIDP• Demyelination is demonstrated
on nerve conduction study by the presence of conduction block or temporal dispersion in the CMAPs.
• Motor nerve conduction velocity below 80% of the lower limit of normal
• * Provided if these focal abnormalities are present outside commonnerve entrapment sites
![Page 18: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/18.jpg)
• Amplitude of the CMAPs may also be abnormally low, indicating concomitant axonal loss.
• Axonal loss accumulates as the disease progresses. This complicates the interpretation of nerve conduction velocity, as axonal loss alone can lead to some conduction slowing.
• F waves may be delayed or unrecordable.• Demyelination in CIDP is patchy or multifocal,
with different nerve segments affected to different degrees but in hereditary forms (CMT) the pattern is uniform and conduction block is uncommon
![Page 19: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/19.jpg)
Other Dx tests
• CSF in patients with CIDP shows a moderately elevated protein level without pleocytosis – nonspecific (diabetic neuropathy and infectiousor carcinomatous infiltration of spinal roots)
• Nerve biopsy only when the typical clinical or electrophysiologic features are absent.
• Recurring segmental demyelination and remyelination accompanied by thinly myelinated fibers or a loss of myelinated fibers.
![Page 20: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/20.jpg)
Treatment of CIDP
![Page 21: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/21.jpg)
Chronic Inflammatory Demyelinating Polyneuropathies: Classification By
Weakness and Sensory Loss Patterns
![Page 22: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/22.jpg)
Multifocal Motor Neuropathy
• MMN presents with subacute onset of asymmetric weakness.
• Weakness starts focally as a mononeuropathy, usually in the distal upper limbs ---> spread to contralateral hand, and both legs
• Fasciculations and cramps +/-, muscle bulk maintained until late in the disease.
• DTR – diminished/normal/brisk• Involvement of the cranial nerves, bulbar muscles,
phrenic nerves, and respiratory muscles - rare
![Page 23: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/23.jpg)
• The CSF protein is normal in multifocal motor neuropathy.
• Approximately half of patients with MMN have elevated serum antibodies directed against gangliosides, especially GM1
• EMG: patchy focal demyelination in motor nerves with conduction block and normal sensory nerve conduction study
• Multifocal motor neuropathy primarily responds only to IV immunoglobulin.
![Page 24: Immune mediated neuropathies](https://reader035.vdocuments.site/reader035/viewer/2022062412/58f134a71a28ab60758b45e5/html5/thumbnails/24.jpg)
THANK YOU